CymaBay Therapeutics (CBAY) Stock Rating Lowered by Zacks Investment Research

... biopharmaceutical company's stock valued at $100,000 after purchasing an additional 140 shares during the period. Ardsley Advisory Partners grew its stake in shares of CymaBay Therapeutics by 66.2% during the 2nd quarter. Ardsley Advisory Partners ...
http://ift.tt/2mDdnHL